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ABSTRACT 
Lycopene is used for the treatment of cancer and cardiovascular disease and Ubidecarenone is used as a dietary supplement and 
categorized as cardiovascular agent used for the treatment of heart failure and cardiac disorder. A Reverse Phase Liquid 
Chromatography (RP–HPLC) method was developed and validated for the simultaneous estimation of Lycopene and 
Ubidecarenone in combined pharmaceutical dosage form. The different analytical parameters such as linearity, range, precision, 
accuracy, and robustness were determined according to the International Conference on Harmonization ICH Q2 R (1) guidelines. 
Chromatography was carried out by Isocratic technique at a flow rate of 1.5 ml/min on Waters Reliant C18 (150 X 4.6mm I.D., 
5µm particle size) column at 50. The mobile phase consists of mixture of methanol:tetrahydrofuran:acetonitrile:water in the ratio 
of 25:15:58:2 % v/v and optimized depending upon the polarity. The UV detection wavelength was 400 nm and 50 µL of sample 
was injected. The retention times of Lycopene and Ubidecarenone were found to be 11.126 min and 20.504 min respectively. The 
calibration curves were linear over the concentrations 13-38 mcg/mL and 188-563 mcg/mL with correlation coefficient of 0.9986 
and 0.9989, for Lycopene and Ubidecarenone. Percentage recovery obtained 98.58-100.15 % for Lycopene and 99.30-100.64 % 
for Ubidecarenone. The % RSD for Precision and Accuracy of the method was found to be NMT 2%. The proposed method was 
highly sensitive, precise and accurate. Hence, the method was successfully applied for the reliable quantification of active 
pharmaceutical ingredient content in in-house prepared tablet formulation.  
Key words: Lycopene, Ubidecarenone, RP - HPLC, Validation, Simultaneous estimation, % RSD. 
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INTRODUCTION 
Lycopene is chemically 2, 6, 10, 14, 19, 23, 27, 31- 
Octamethyldotriaconta- 2, 6, 8, 10, 12, 14, 16, 18, 20, 
22, 24, 26, 30- tridecaene (Figure 1). Lycopene does 
not have a Pro-vitamin A activity
1
. Lycopene is 
regarded as a strong antioxidant and have a protective 
effect against Prostate cancer
2,3
. Lycopene is the only 
carotenoid associated with cancer risk reduction and its 
plasma concentration is also considered as a useful 
clinical parameter associated with myocardial 
infarction
4
. Ubidecarenone is chemically 2- [(2E, 6E, 
10E, 14E, 18E, 22E, 26E, 30E, 34E)- 3,7,11,15,19, 23, 
27, 31, 35, 39- Decamethyltetraconta- 2, 6,10,14,18, 
22, 26, 30, 34, 38- decaenyl]- 5, 6- dimethoxy-3- 
methylcyclohexa- 2, 5- diene-1,4- dione (Figure 2). It 
is also known as Coenzyme Q10 and used as a dietary 
supplement. It is categorized as a cardiovascular agent 
used in the treatment of congestive cardiac failure and 
angina pectoris
5
. It increases the contractive force of 
the heart through positive inotropic action to improve 
cardiac output.  
The Literature survey shows that there are few 
analytical methods reported for the determination of 
Lycopene and Ubidecarenone in pharmaceutical 
dosage forms either as a single drug or in combination 
with some other drugs. Lycopene has been determined 
in food, biological samples and pharmaceutical dosage 
form by various analytical methods, such as, 
Supercritical Fluid Chromatography
6
 (SFC), RP-
HPLC
7-10
, HPLC with UV-
Detection
11,12
.Ubidecarenone has been determined by 
analytical methods either individually
13,14
 or in 
combination with other drugs by UV
15
, RP-HPLC
16-19
. 
 
Figure 1: Chemical structure of Lycopene 
 
Figure 2: Chemical structure of Ubidecarenone 
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However, there is no HPLC method reported for the 
simultaneous estimation of Lycopene and 
Ubidecarenone in Pharmaceutical dosage forms. The 
present paper describes a simple, rapid, economical and 
accurate RP-HPLC method for the simultaneous 
estimation of Lycopene and Ubidecarenone in 
Pharmaceutical dosage form. The method was 
validated
20
 in compliance with ICH Q2 R (1) 
guidelines. 
EXPERIMENTAL 
Chemicals and reagents 
Methanol HPLC Grade, Tetrahydrofuran HPLC Grade, 
Acetonitrile HPLC Grade, Water HPLC Grade, and 
Ethanol HPLC Grade were used. The standard samples 
of Lycopene and Ubidecarenone were obtained as gift 
samples from Sai Mirra Innopharm Pvt. Ltd., Chennai 
with purity of 10.21 % for Lycopene and 99.98 % for 
Ubidecarenone. The tablet formulation (Blesspa) is 
also obtained from Sai Mirra Innopharm pvt. Ltd., 
Chennai. Each table contains about 20 mg of Lycopene 
and 300 mg of Ubidecarenone. 
Apparatus and Instrument 
The analysis was carried out using Shimadzu LC 
2010A HT system with LC solution software. The 
system was equipped with LC-20 ATVP series pump, 
Autosampler, and UV - Visible detector SPD 20A. 
Other apparatus and instruments used were UV-Visible 
Spectrophotometer (UV-1601 SHIMADZU) with UV-
Probe software, Analytical balance (Uni Bloc), pH 
meter (Spectrum Tek), Vaccum pump (Gelchem 
science), Sonicator (Spectrum Tek). All the 
instruments and glass wares were calibrated.  
Mobile Phase 
The mobile phase consists of mixture of 
methanol:tetrahydrofuran:acetonitrile:water in the ratio 
of 25:15:58:2 % v/v. The mobile phase was filtered 
through Millipore filter paper type HV (0.45 µm) and 
degassed by ultrasonication for 10 minutes. 
Chromatographic conditions 
Chromatographic analysis was carried out on a Waters 
reliant C18, (150 mm x 4.6 mm I.D., 5µm) was used 
for separation. The mobile phase consisted of mixture 
of methanol:tetrahydrofuran:acetonitrile:water in the 
ratio of 25:15:58:2 % v/v. The flow rate was delivered 
at 1.5 mL/min with detection wavelength at 400 nm. A 
50 µL sample solution was injected to the 
chromatographic system with column temperature of 
50. Under these conditions the run time was 35 min. 
Preparation of standard stock solution of Lycopene 
and Ubidecarenone 
Stock solution was prepared by taking 25 mg of 
Lycopene and 37.5 mg of Ubidecarenone working 
standard in a 50 mL volumetric flask. 15 ml of DMF 
was added and sonicated for about 20 min until all the 
contents has been dissolved completely. Then, the 
remaining volume was made up to the mark with 
ethanol and filtered through 0.45 PVDF filter. The 
further dilutions were done using diluent 
ACN:Methanol (60:40) v/v. 
Preparation of combined working standard of 
Lycopene and Ubidecarenone 
The standard stock solution was diluted further to get 
the concentrations in the range of 12.5, 20, 25, 30, 37.5 
µg/mL Lycopene and 187.5, 300, 375, 450, 562.5 
µg/mL Ubidecarenone. The calibration curve was 
plotted by taking six different concentrations from the 
stock solution and all the six injections were injected 
into the chromatographic system and chromatograms 
were recorded. 
Assay Procedure
21 
 Accurately about 20 tablets were weighed and the 
average weight was taken. The tablets were powdered 
finely and tablet powder equivalent to 25 mg of 
Lycopene and 37.5 mg of Ubidecarenone were taken 
into 100mL volumetric flask. About 50mL of ethanol 
was added and sonicated for about 20 min until all the 
contents were dissolved which was made up to the 
mark with mobile phase. The above solution was 
filtered through 0.45 PVDF filter with discarding first 
10mL of the filtrate. With optimized chromatographic 
condition a steady baseline was recorded with mobile 
phase. About 50µL of the sample solution was injected 
and the chromatogram was recorded. 
  
 
Table 1: Results of Assay 
Drug Name Label Claim (mg) Amount found (mg) % Content* 
Lycopene 20 20.25 101.25 
Ubidecarenone 300 294.62 98.43 
(n = 3)* 
 
Method Validation 
Precision 
Precision is the degree of repeatability of an analytical 
method under normal conditions. System precision 
was performed by injecting six replicate injections of 
Lycopene and Ubidecarenone (25 ppm of Lycopene 
and 37.5 ppm of Ubidecarenone) working standard. 
The precision of test method was evaluated by 
performing assay for six individual test preparations of 
20/300 mg strength as per test method. About 50 µL of 
the solution was injected and the chromatograms were 
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recorded. The procedures for system and method 
precision were repeated for 6 times. The peak areas 
were measured and the % relative standard deviation 
was calculated. 
Linearity 
The linearity of measurements was evaluated by 
analyzing six different concentrations of the standard 
solutions of Lycopene and Ubidecarenone in the range 
of 13-38 mcg/mL and 188-563 mcg/mL for both drugs 
respectively and a calibration plot was constructed. 
The linearity was evaluated by linear regression 
analysis. 
Accuracy 
The accuracy was confirmed by recovery studies by 
adding known amount of placebo to the pure API of 
Lycopene and Ubidecarenone from about 50 % to 150 
% of the initial assay concentration. Sample solutions 
was prepared in triplicate for each level and analyzed 
as per test method. 
Robustness 
 Influence of deliberate change in the chromatographic 
conditions such as change in flow rate of 1.4 and 1.6 
mL/min, change in wavelength of 398 and 402 nm, 
and change in mobile phase composition of 
methanol:tetrahydrofuran:acetonitrile:water 
(23:15:60:2) % v/v and 
methanol:tetrahydrofuran:acetonitrile:water 
(27:15:56:2) % v/v was made to evaluate the impact of 
the method. The mixed standard solution is injected in 
six replicate and % RSD was calculated. 
Ruggedness 
The ruggedness of the method was demonstrated by 
conducting the precision study on different HPLC system 
(1 & 2) and performed by different analyst on different 
day. Assay was performed for six individual test 
preparations of 20/300 mg strengths as per test methods. 
From the peak of the chromatograms, the % RSD was 
calculated. 
Specificity 
Specificity is the ability to assess unequivalently the 
analyte in the presence of components, which may be 
expected to be present. Typically these might include 
impurities, matrix, degradants etc. Specificity is 
evaluated for blank and placebo interference by 
injecting the blank and the control sample solution 
prepared as per the proposed method. It is used to 
check for the interference of any peak at the retention 
time of Lycopene and Ubidecarenone. 
System suitability 
System suitability study of the method was carried out 
by six replicate analysis of solution containing 100% 
target concentration of Lycopene and Ubidecarenone. 
The system suitability parameters like USP plate 
count, asymmetry factor, retention time, resolution, 
tailing factor were evaluated from standard 
chromatogram. 
Stability of solution 
 A study to establish the stability of standard and test 
preparation on bench top was conducted for 1, 2, 4, 8, 
10 Hours. 
RESULTS AND DISSCUSSION 
 
 
Figure 3: UV spectrum of Lycopene and 
Ubidecarenone  
 
Selection of Detection wavelength 
The wavelength selected was from the overlay of 
Lycopene and Ubidecarenone. Both the drugs showed 
typical peak nature and the peaks were symmetrical at 
400 nm. Hence the wavelength has been selected as 
the detection wavelength. 
Development and optimization of the HPLC 
method 
For getting an optimized chromatographic condition a 
Waters Reliant C18 (150 X 4.6mm I.D., 5µm particle 
size) column was selected as a stationary phase. The 
mobile phase composition of a mixture of 
methanol:tetrahydrofuran:acetonitrile:water in the ratio 
of 25:15:58:2 % v/v was selected which gave good 
resolution and asymmetry. The flow rate of 1.5 mL 
and column temperature of 50was selected. The 
retention time for Lycopene and Ubidecarenone was 
found to be 11.126 min and 20.504 min respectively.  
Validation 
Linearity 
The linearity study was conducted for the Lycopene 
and Ubidecarenone by preparation of the stock 
solution using the ethanol. Calibration curve was 
plotted by taking six concentrations in the range of 13 
mcg/mL- 38 mcg/mL for Lycopene 188 mcg/mL-563 
mcg/mL for Ubidecarenone. The slope, intercept, and 
correlation coefficient of Lycopene was found to be 
4065, 846, 0.9989 and for Ubidecarenone was found to 
be 1254, 734, 0.9986. The data regarding linearity was 
shown in Table 2. Calibration curves of Lycopene and 
Ubidecarenone were shown in Figure: 4 and 5.
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Table 2: Linearity data 
                Lycopene               Ubidecarenone 
% Level Concentration 
(mcg/mL) 
Peak area Concentration 
(mcg/mL) 
Peak area 
50 12.5 51733 187.5 242066 
80 20.0 83593 300 375082 
100 25.0* 100730 375* 460885 
120 30.0 122172 450 567228 
150 37.5 154205 562.5 711012 
* Operating concentration 
 
 
Figure 4: Calibration curve of Lycopene 
 
Figure 5: Calibration curve of Ubidecarenone
 
Precision 
System precision was performed using six replicated 
injections of Lycopene (25 ppm) and Ubidecarenone 
(37.5 ppm) working standard into the HPLC system 
from the stock solution. The % RSD for peak area of 
Lycopene and Ubidecarenone from six replicate 
injections of standard solution was found to be NMT 
2.0. The precision of test method was evaluated by 
performing assay for six individual test preparations of 
20/300 mg strength as per test method. The % RSD of 
the six assay values should was found to be not more 
than 2.  
 
Table 3: System precision 
Injection Number Lycopene Peak area Ubidecarenone Peak area 
1 115029 477434 
 
2 115372  480062 
3 115086 481810 
4 115765 477844 
5 115565 480530 
6 115435 481519 
Average 115375.3 479866.5 
SD 256.5947951 1682.9519 
% RSD 0.22 0.35 
 
Table 4: Method precision 
S. No Area % Assay Area % Assay 
Lycopene Label claim 20mg Ubidecarenone Label claim 300mg 
1 115601 20.28 mg (101.40%) 478700 295.97 mg (98.66%) 
2 116292 20.24 mg (101.20%) 483642 295.16 mg (98.39%) 
3 116929 20.28 mg (101.40%) 485875 291.81 mg (97.27%) 
4 116320 19.98 mg (99.90%) 479028 291.63 mg (98.54%) 
5 116040 20.22 mg (101.10%) 483614 296.94 mg (98.98%) 
6 117720 20.50 mg (102.50%) 486878 296.23 mg (98.74%) 
 Mean 20.25 mg (101.25%) Mean 294.62mg (98.43%) 
 %RSD 0.83% %RSD 0.61% 
y = 4065.x + 845.5 
R² = 0.9989 
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Accuracy: 
The accuracy was confirmed by recovery studies by 
adding known amount of placebo to the pure API of 
Lycopene and Ubidecarenone at about three levels. 
Sample solution was prepared in triplicate for each 
level and analyzed as per test method. The amount 
spiked and the mean recovery values were calculated. 
The % RSD was found to be NMT 2%.
 
 
Table 5: Accuracy data 
Drug Amount of Lycopene 
spiked (mg) 
Amount 
recovered (mg) 
% Recovery 
(98% to 102%) 
Mean % Recovery 
and % RSD 
Lycopene 2.5545 2.5553 100.02 Mean = 99.59% 
% RSD=0.67% 2.5525 99.92 
2.5245 98.82 
Ubidecarenone 37.5225 38.0979 101.53 Mean = 100.64% 
% RSD=0.77% 37.5558 100.09 
37.6370 100.31 
 
Robustness 
As part of the robustness, deliberate change in the flow 
rate at 1.4 and 1.6 mL/min, wavelength at 402 nm and 
398 nm, and mobile phase composition such as 
methanol:tetrahydrofuran:acetonitrile:water in the ratio 
of 23:15:60:2 % v/v and 27:15:56:2 % v/v was made to 
evaluate the impact of the method. The mixed standard 
solution was injected in six replicate. The % RSD and 
the system suitability parameters were calculated. The 
% RSD of areas of Lycopene and Ubidecarenone for 6 
replicate standard injections was found to be NMT 
2.0%. The tailing factor for both the peaks was found to 
be NMT 2.0. The column efficiency was found to be 
NLT 2000 theoretical plates and the resolution between 
the two peaks was found to be NLT 5.0. 
 
Table 6: Robustness data for Lycopene 
 
Parameters 
 
Variation 
Lycopene 
% RSD Tailing factor Theoretical plate 
Flow rate 
(mL/min) 
1.4 0.94 1.420 6504.166 
1.6 0.82 1.436 8080.108 
Wavelength 
(nm) 
398 1.25 1.423 6044.404 
402 1.23 1.420 6218.216 
Mobile phase 
ratio 
 23:15:60:2 0.64 1.195 8459.057 
 27:15:56:2 0.75 1.203 9295.619 
 
                                                      Table 7: Robustness data for Ubidecarenone 
 
Parameters 
 
Variation 
Ubidecarenone  
% RSD Tailing Factor Theoretical Plate Resolution 
Flow rate 
(mL/min) 
1.4 0.85 1.229 6577.089 13.164 
1.6 0.12 1.224 8104.396 14.833 
Wavelength (nm) 398 0.49 1.242 6524.340 12.952 
402 0.52 1.249 6531.517 13.024 
Mobile phase ratio  23:15:60:2 0.22 1.197 8252.140 14.381 
 27:15:56:2 0.35 1.193 9162.936 14.909 
 
  
 
 
 
 
 
 
 
Figure 6: Optimized chromatogram 
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System suitability 
The System suitability parameters were calculated, and the 
values were found to be within the limit. From the system 
suitability parameters the method was found to be linear with 
good resolution and symmetry. 
 
Table 8: System suitability parameters 
System Suitability Parameters Observed Values 
Lycopene Ubidecarenone 
Retention time 12.455 24.875 
USP plate count 10818.229 12521.263 
Resolution - 16.672 
Tailing factor 1.474 1.282 
Linearity (µg/mL) 13- 38 188 -563 
Correlation coefficient (R2) 0.9989 0.9986 
Slope (m) 4065 1254 
Intercept (c) 845.5 733.5 
 
CONCLUSION 
A precise RP–HPLC method was developed for the 
simultaneous estimation of Lycopene and Ubidecarenone 
showed good precision and accuracy. The low % RSD values in 
the recovery studies for the method shows that there are no 
interferences due to excipients during formulation. Hence it was 
concluded that the developed method was simple, precise and 
rapid for the analysis of combination of Lycopene and 
Ubidecarenone. The method was validated as per the ICH Q2 
(R1) guidelines.  
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